The proceeds will be used to advance its gene-editing product pipelines.
Gene editing
Recently, Lumiere Therapeutics (Chinese: 微光基因) announced the completion of the Angel round of financing worth nearly CNY 100 million (USD 14.8 million).
This round is led by Apricottree Capital (Chinese: 杏泽资本). The funding will be mainly used to accelerate the development of product pipelines and the R&D of next-generation gene-editing platform.
Lumiere Therapeutics, founded by Professor Song Yangzhou in 2021, focuses on developing CRISPR-based gene-editing tools and gene therapies, dedicated for the commercialization of next-generation gene-editing technology.
Professor Song served as the the president of Chinese Academy of Sciences and has made world-class original contributions in the fields of molecular cytology, protein science and aging. The reseach team at Lumiere Therapeutics, equipped with rich experience in the field of gene editing, have developed proprietary next-generation editing tools and safety evaluation technology platforms. It is expected that the first application of Investigational New Drug (IND) of a product pipeline wil be submitted in 2023.
Lumiere Therapeutics’s competitors include Prime Medicine, GenEditBio and AccureEdit Therapeutics.
Computing power is productivity: An infrastructure competition concerning the next ten years
May 20, 2026 11:05 AM
From a "Huawei substitute" to falling out of the top five: Where exactly did Honor lose?
May 19, 2026 12:00 PM